This trial is testing a new cancer treatment to see if it is safe and effective. People with advanced cancer who have not had success with other treatments are eligible to participate. The treatment consists of a new medication, BI 765179, given alone or with another medication, ezabenlimab. The study will last up to three years, and participants will be closely monitored for any side effects.
2 Primary · 9 Secondary · Reporting Duration: up to 36 months
Awards & Highlights
2 Treatment Groups
Arm A: BI 765179
1 of 2
Arm B: BI 765179 + ezabenlimab
1 of 2
160 Total Participants · 2 Treatment Groups
Primary Treatment: BI 765179 · No Placebo Group · Phase 1
Who is running the clinical trial?
Age 18+ · All Participants · 1 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
What is the total enrollment of this research project?
"Affirmative. The information on clinicaltrials.gov verifies that this investigation is currently enrolling patients and was initially published on September 24th 2021. 150 individuals need to be recruited across 2 sites, with a recent update done November 2nd 2022." - Anonymous Online Contributor
Are recruitment efforts currently underway for this investigation?
"That's accurate. According to clinicaltrials.gov, this medical experiment began recruiting on September 24th 2021 and is still taking applications today as per its last update from November 2nd 2022. 150 volunteers are necessary for the project at two separate sites of study." - Anonymous Online Contributor
Has the FDA sanctioned BI 765179 for public use?
"Due to its early stage status, BI 765179's safety can only be estimated at a score of 1. There is limited data available in terms of efficacy and overall security for this drug candidate." - Anonymous Online Contributor